Baxter to establish new innovation and R&D center in Cambridge, MA

BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new lease for approximately 200,000 square feet for 12 years with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., at 650 East Kendall Street in Cambridge, Massachusetts, which is owned by BioMed Realty through a joint venture with Prudential Real Estate Investors. Baxter will be establishing a new global innovation and research and development (R&D) center at the site for its biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Incorporated in mid-2015.

The 650 East Kendall building is a 282,000 square foot life science facility that is supported by six levels of below-grade parking. Located in close proximity to the campuses of M.I.T. and Harvard, and designed by famed architect Paul Zejfen, the building features a spacious atrium with stairs connecting its six floors of laboratory and office space, interior balconies and exterior terraces, creating an environment that facilitates the collaboration of employees and researchers. The building received Gold status certification by the Leadership in Energy and Environmental Design (LEED®) of the U.S. Green Building Council.

Alan D. Gold, BioMed Realty's Chairman and Chief Executive Officer, commented, "We are very proud to welcome Baxter to Kendall Square and our 650 East Kendall building. Baxter is a global healthcare leader with an amazing track record of scientific achievement, commercialization and corporate responsibility. By forging this long-term connection with Baxter in Cambridge, we have the opportunity to support their technological expertise and scientific innovation for many years to come, and we look forward to providing the best environment for their business and employees to continue their great work."

"We are honored that Baxter has chosen 650 East Kendall Street to be its flagship location in Cambridge," remarked William Kane, BioMed Realty's Vice President of Leasing & Development. "The building is supremely well-located in an architecturally and culturally diverse environment that is unique to Kendall Square. Along with its flexible, intelligent design, which incorporates the best practices in building infrastructure and operations, the location of 650 East Kendall Street offers Baxter's employees immediate access to the distinctive surrounding amenities, including kayaking on the Charles River and a weekly farmers' market in the summer, ice skating in the winter, and year-long access to a wide variety of retail restaurants and shops. In short, it is a world-class facility for a world-class company."

Concurrently, BioMed Realty executed a lease termination with an existing tenant in the building. As a result of these transactions, 650 East Kendall is now 100% leased.



BioMed Realty Trust, Inc.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 19). Baxter to establish new innovation and R&D center in Cambridge, MA. News-Medical. Retrieved on April 25, 2024 from

  • MLA

    Baxter International Inc.. "Baxter to establish new innovation and R&D center in Cambridge, MA". News-Medical. 25 April 2024. <>.

  • Chicago

    Baxter International Inc.. "Baxter to establish new innovation and R&D center in Cambridge, MA". News-Medical. (accessed April 25, 2024).

  • Harvard

    Baxter International Inc.. 2019. Baxter to establish new innovation and R&D center in Cambridge, MA. News-Medical, viewed 25 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A